Logo image of CNCK

COINCHECK GROUP NV (CNCK) Stock Fundamental Analysis

NASDAQ:CNCK - Nasdaq - NL0015002BV9 - Common Stock - Currency: USD

5.06  -0.53 (-9.48%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CNCK. CNCK was compared to 231 industry peers in the Capital Markets industry. CNCK has a bad profitability rating. Also its financial health evaluation is rather negative. CNCK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CNCK has reported negative net income.
CNCK had a negative operating cash flow in the past year.
CNCK Yearly Net Income VS EBIT VS OCF VS FCFCNCK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 2M -2M 4M

1.2 Ratios

CNCK has a Return On Assets of -0.84%. This is in the lower half of the industry: CNCK underperforms 77.92% of its industry peers.
The Return On Equity of CNCK (-1.09%) is worse than 75.32% of its industry peers.
Industry RankSector Rank
ROA -0.84%
ROE -1.09%
ROIC N/A
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNCK Yearly ROA, ROE, ROICCNCK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 5 10 15

1.3 Margins

CNCK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNCK Yearly Profit, Operating, Gross MarginsCNCK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CNCK has been reduced compared to 1 year ago.
The debt/assets ratio for CNCK is higher compared to a year ago.
CNCK Yearly Shares OutstandingCNCK Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
CNCK Yearly Total Debt VS Total AssetsCNCK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

CNCK has an Altman-Z score of 60.10. This indicates that CNCK is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 60.10, CNCK belongs to the top of the industry, outperforming 99.13% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that CNCK is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, CNCK belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 60.1
ROIC/WACCN/A
WACCN/A
CNCK Yearly LT Debt VS Equity VS FCFCNCK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

CNCK has a Current Ratio of 0.00. This is a bad value and indicates that CNCK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CNCK (0.00) is worse than 94.37% of its industry peers.
A Quick Ratio of 0.00 indicates that CNCK may have some problems paying its short term obligations.
With a Quick ratio value of 0.00, CNCK is not doing good in the industry: 94.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0
Quick Ratio 0
CNCK Yearly Current Assets VS Current LiabilitesCNCK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CNCK have decreased strongly by -118.29% in the last year.
EPS 1Y (TTM)-118.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNCK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNCK Price Earnings VS Forward Price EarningsCNCK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNCK Per share dataCNCK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CNCK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COINCHECK GROUP NV

NASDAQ:CNCK (5/29/2025, 8:00:00 PM)

5.06

-0.53 (-9.48%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.54%
Inst Owner Change-7.74%
Ins OwnersN/A
Ins Owner Change0%
Market Cap661.90M
AnalystsN/A
Price TargetN/A
Short Float %1.39%
Short Ratio3.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 27.21
P/tB 27.21
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.84%
ROE -1.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0
Quick Ratio 0
Altman-Z 60.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-118.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-262.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-262.42%
OCF growth 3YN/A
OCF growth 5YN/A